All News

The approval for osimertinib/chemotherapy by the Japanese Pharmaceuticals and Medical Device Agency was based on results from the phase 3 FLAURA2 trial.

Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.

More than half of the patients who received mitazalimab plus chemotherapy experienced an unconfirmed objective response in the phase 2 OPTIMIZE-1 study.

Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.

Durvalumab improved efficacy in patients with muscle-invasive bladder cancer.

Vikek S. Kavadi, MD, MBA, FASTRO, succeeds Laura Thevenot, who plans to retire at the end of 2024 after leading the organization since 2002.

Two deaths due to presumed sepsis in patients treated in the DENALI trial led to the clinical holds on the advanced solid tumor treatment.

Longer survival rates were experienced by patients receiving chemotherapy both before and after surgery vs only after surgery.

Approved for use in newly diagnosed and previously treated myelofibrosis, momelotinib may addresses key manifestations of the disease.

Data from FRESCO-2 support the approval of fruquintinib for those with previously treated metastatic colorectal cancer in the European Union.

Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.

Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.

As the practice of radiation therapy evolves in HPV-associated OPSCC, updated evidence-based ASTRO guidelines may help inform clinical practices.

Data from the colorectal cancer cohort of the KRYSTAL-1 trial support the accelerated approval of adagrasib/cetuximab in KRAS G12C–mutated disease.

Joleen Hubbard, MD, explains why allowing access to results can improve patient’s outlook on treatments and understanding of their disease.

The European Medicines Agency will begin a centralized review process for subcutaneous nivolumab across multiple solid tumor indications.

Golidocitinib monotherapy had a superior clinical benefit in patients with relapsed/refractory peripheral T-cell lymphoma vs existing treatments.

Compared with cognitively-defined and hemigland contours, AI-assisted cancer contours delivered a greater balanced accuracy rate.

Data from CAPItello-291 support the approval of capivasertib/fulvestrant for ER-positive, HER2-negative breast cancer in the European Union.

A minimally invasive cryoablation technology system designed to treat patients with kidney tumors and elicit an 89.65% recurrence-free rate.

Findings from a retrospective study showed that outpatient robotic hepatectomies resulted in no mortalities across 307 procedures.

Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.

Phase 1 data show no dose-limiting toxicities with sonrotoclax plus zanubrutinib for patients with relapsed/refractory CLL or SLL.

Data from the phase 3b JUMP trial support the use of ruxolitinib in myelofibrosis regardless of baseline or treatment-related anemia.

Capivasertib's safety profile in the CAPItello-290 trial was comparable with prior reports of the agent in advanced triple-negative breast cancer.